Lyric Bio, Inc. has secured $7,000,000 in investment capital from investors. The company is dedicated to reshaping the global supply of life-saving medicines through its next-generation biomanufacturing platform. This funding marks a significant step in its mission to address critical shortages of essential therapies, such as intravenous immunoglobulin (IvIg), relied upon by thousands of patients with immune deficiencies and neurological disorders.
The global IvIg market, valued at over $20 billion, faces persistent supply limitations despite projected strong growth. Traditional plasma-derived processes struggle to keep pace with rising demand, leading to ongoing shortages for patients and clinicians. Lyric Bio positions itself at the forefront of this challenge, developing scalable and efficient production technology designed to overcome these long-standing bottlenecks in access.
This capital infusion will enable Lyric Bio to accelerate the development and commercialization of its groundbreaking technology. The funds are planned to be used for strategic growth initiatives, including advancing its proprietary biomanufacturing platform and scaling operations to increase the availability of high-quality therapies. This investment is crucial for expanding the company’s capacity to deliver innovative solutions to the market.
For patients, Lyric Bio’s innovation offers the promise of consistent and reliable access to vital treatments. By reimagining how essential biologics like IvIg are made, the company is also laying the groundwork for the first in vitro production of other donor-derived complex therapeutics, such as stem cells and red blood cells. Lyric Bio anticipates this funding will propel its expansion and solidify its role in revolutionizing the supply chain for critical medical treatments.
